EcoDrugPlus

40s Ribosomal Protein Sa

Ensembl ID : ENSSTUG00000007304
Gene Symbol: LOC115147211
3 Cross references
499 Possible Orthologues:

40s Ribosomal Protein Sa

Ensembl ID : ENSSTUG00000045701
Gene Symbol: LOC115178524
3 Cross references
500 Possible Orthologues:

40s Ribosomal Protein Sa-Like

Ensembl ID : ENSSTUG00000002092
Gene Symbol: LOC115201462
3 Cross references
503 Possible Orthologues:

5'-Nucleotidase-Like

Ensembl ID : ENSSTUG00000046973
Gene Symbol: LOC115194538
3 Cross references
207 Possible Orthologues:

5'-Nucleotidase-Like

Ensembl ID : ENSSTUG00000047319
Gene Symbol: LOC115174945
3 Cross references
207 Possible Orthologues:

5'-Nucleotidase-Like

Ensembl ID : ENSSTUG00000051027
Gene Symbol: LOC115172841
3 Cross references
178 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a-Beta-Like

Ensembl ID : ENSSTUG00000016972
Gene Symbol: LOC115160228
3 Cross references
137 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSTUG00000047061
Gene Symbol: HTR1B
1 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSTUG00000047370
Gene Symbol: HTR1B
1 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSTUG00000051026
Gene Symbol: HTR1B
1 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSTUG00000032879
Gene Symbol: HTR1B
1 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSSTUG00000045818
Gene Symbol: HTR1E
1 Cross references
140 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).